Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

290

Enrollment

NIH

Sponsor class

Conditions

Kidney Transplant

Interventions

BIOLOGICAL: Infliximab
DRUG: Methylprednisolone
DRUG: Mycophenolate Mofetil
DRUG: Tacrolimus
BIOLOGICAL: Thymoglobulin®
DRUG: Acetaminophen
DRUG: Loratadine
BIOLOGICAL: Placebo for Infliximab
DRUG: Prednisone
DRUG: Diphenhydramine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]